EcoDrugPlus

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSSTUG00000009975
Gene Symbol: LOC115193627
3 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSSTUG00000037465
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSSTUG00000017403
Gene Symbol: ERBB3
3 Cross references
205 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSSTUG00000003773
Gene Symbol: ERBB3
3 Cross references
205 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSSTUG00000035994
Gene Symbol: ERBB4
3 Cross references
8 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSSTUG00000050216
Gene Symbol: ERBB4
3 Cross references
9 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSSTUG00000018990
Gene Symbol: ESR1
3 Cross references
207 Possible Orthologues:

Estrogen Receptor 2b

Ensembl ID : ENSSTUG00000038959
Gene Symbol: ESR2B
1 Cross references
202 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSSTUG00000029385
Gene Symbol: LOC115174660
3 Cross references
198 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSSTUG00000045577
Gene Symbol: LOC115172515
3 Cross references
203 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSSTUG00000039695
Gene Symbol: LOC115162231
3 Cross references
202 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSSTUG00000040315
Gene Symbol: LOC115161802
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).